» Articles » PMID: 35881280

Functional and Metabolic Imaging in Heart Failure with Preserved Ejection Fraction: Promises, Challenges, and Clinical Utility

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Heart failure with preserved ejection fraction (HFpEF) is recognised as an increasingly prevalent, morbid and burdensome condition with a poor outlook. Recent advances in both the understanding of HFpEF and the technological ability to image cardiac function and metabolism in humans have simultaneously shone a light on the molecular basis of this complex condition of diastolic dysfunction, and the inflammatory and metabolic changes that are associated with it, typically in the context of a complex patient. This review both makes the case for an integrated assessment of the condition, and highlights that metabolic alteration may be a measurable outcome for novel targeted forms of medical therapy. It furthermore highlights how recent technological advancements and advanced medical imaging techniques have enabled the characterisation of the metabolism and function of HFpEF within patients, at rest and during exercise.

Citing Articles

Myocardial metabolic flexibility following ketone infusion demonstrated by hyperpolarized [2-C]pyruvate MRS in pigs.

Bech S, Hansen E, Nielsen B, Wiggers H, Bengtsen M, Laustsen C Sci Rep. 2025; 15(1):5849.

PMID: 39966569 PMC: 11836332. DOI: 10.1038/s41598-025-90215-9.


Lifestyle interventions in cardiometabolic HFpEF: dietary and exercise modalities.

Vacca A, Wang R, Nambiar N, Capone F, Farrelly C, Mostafa A Heart Fail Rev. 2024; .

PMID: 39283525 DOI: 10.1007/s10741-024-10439-1.


Myocardial Metabolism in Heart Failure with Preserved Ejection Fraction.

Henry J, Couch L, Rider O J Clin Med. 2024; 13(5).

PMID: 38592048 PMC: 10931709. DOI: 10.3390/jcm13051195.


Positron Emission Tomography in Heart Failure: From Pathophysiology to Clinical Application.

Tersalvi G, Beltrani V, Grubler M, Molteni A, Cristoforetti Y, Pedrazzini G J Cardiovasc Dev Dis. 2023; 10(5).

PMID: 37233187 PMC: 10218989. DOI: 10.3390/jcdd10050220.

References
1.
Rayner J, Peterzan M, Watson W, Clarke W, Neubauer S, Rodgers C . Myocardial Energetics in Obesity: Enhanced ATP Delivery Through Creatine Kinase With Blunted Stress Response. Circulation. 2020; 141(14):1152-1163. PMC: 7144750. DOI: 10.1161/CIRCULATIONAHA.119.042770. View

2.
Lindman B, Davila-Roman V, Mann D, McNulty S, Semigran M, Lewis G . Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol. 2014; 64(6):541-9. PMC: 4133145. DOI: 10.1016/j.jacc.2014.05.030. View

3.
Wisneski J, Stanley W, Neese R, Gertz E . Effects of acute hyperglycemia on myocardial glycolytic activity in humans. J Clin Invest. 1990; 85(5):1648-56. PMC: 296617. DOI: 10.1172/JCI114616. View

4.
Wilson J, Rayos G, Yeoh T, Gothard P, Bak K . Dissociation between exertional symptoms and circulatory function in patients with heart failure. Circulation. 1995; 92(1):47-53. DOI: 10.1161/01.cir.92.1.47. View

5.
Abdurrachim D, Teo X, Woo C, Chan W, Lalic J, Lam C . Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized C magnetic resonance spectroscopy study. Diabetes Obes Metab. 2018; 21(2):357-365. PMC: 6587455. DOI: 10.1111/dom.13536. View